|
(4R,5R)-1-[[4-[[4-[3,3-Dibutyl-7-(dimethylamino)-2,3,4,5-tetrahydro-4-hydroxy-1,1-dioxido-1-benzothiepin-5-yl]phenoxy]methyl]phenyl]methyl]-4-aza-l-azoniabicyclo[2.2.2]octane Chloride |
|---|---|
| Trade Name | |
| Orphan Indication | Primary biliary cirrhosis |
| USA Market Approval | USA |
| USA Designation Date | 2013-09-04 00:00:00 |
| Sponsor | Shire Human Genetic Therapies, Inc.;300 Shire Way;Lexington, Massachusetts, 02421 |
